Literature DB >> 9126240

Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.

W K Kelly1, S Slovin, H I Scher.   

Abstract

The steroid withdrawal syndrome has brought a new dimension to the treatment of advanced prostate cancer not only in the way we treat androgen-independent disease but also in terms of insights into the development of hormonal resistance. The data now confirm that 30% of cases have a meaningful subjective, biochemical, and objective response to the withdrawal of a steroid hormone as the first maneuver after primary hormonal therapy failure. Larger studies are needed to define further the withdrawal effect related to the other steroid hormone family members and to determine the objective response proportions. Although controversy surrounds the cause of the steroid withdrawal phenomenon, studies suggest that the androgen receptor plays a pivotal role. Molecular studies of the androgen receptors involving larger number of patients are paramount if we are going to develop a better understanding of the evolution of the withdrawal effect and hormone resistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126240     DOI: 10.1016/s0094-0143(05)70389-x

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  15 in total

1.  Discovery and biological characterization of a novel series of androgen receptor modulators.

Authors:  C Zhou; G Wu; Y Feng; Q Li; H Su; D E Mais; Y Zhu; N Li; Y Deng; D Yang; M-W Wang
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

2.  3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.

Authors:  Hiroshi Miyamoto; Padma Marwah; Ashok Marwah; Henry Lardy; Chawnshang Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

3.  Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells.

Authors:  H C Chang; H Miyamoto; P Marwah; H Lardy; S Yeh; K E Huang; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Pathogenesis of prostate cancer: lessons from basic research.

Authors:  Vamsidhar Velcheti; Satish Karnik; Stephen F Bardot; Om Prakash
Journal:  Ochsner J       Date:  2008

5.  Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.

Authors:  Dana Rathkopf; Glenn Liu; Michael A Carducci; Mario A Eisenberger; Aseem Anand; Michael J Morris; Susan F Slovin; Yasutsuna Sasaki; Shunji Takahashi; Seiichiro Ozono; Nga Kit Eliza Fung; Shinta Cheng; Jinping Gan; Marco Gottardis; Mary T Obermeier; Jyotsna Reddy; Steven Zhang; Blisse J Vakkalagadda; Leila Alland; George Wilding; Howard I Scher
Journal:  Clin Cancer Res       Date:  2010-12-03       Impact factor: 12.531

Review 6.  Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.

Authors:  R Paul; J Breul
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

7.  Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.

Authors:  Cheng-Lung Hsu; Jai-Shin Liu; Po-Long Wu; Hong-Hsiang Guan; Yuh-Ling Chen; An-Chi Lin; Huei-Ju Ting; See-Tong Pang; Shauh-Der Yeh; Wen-Lung Ma; Chung-Jung Chen; Wen-Guey Wu; Chawnshang Chang
Journal:  Mol Oncol       Date:  2014-06-24       Impact factor: 6.603

8.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

9.  Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.

Authors:  H Miyamoto; S Yeh; G Wilding; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.

Authors:  Yiu-Keung Lau; Manpreet K Chadha; Alan Litwin; Donald L Trump
Journal:  J Hematol Oncol       Date:  2008-11-05       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.